Silo Pharma, Inc.
SILONASDAQHealthcare● Active
$6.18
+$0.28(+4.66%)
Market Cap$5586411
P/E Ratio—
52W High$15.15
52W Low$3.315
Silo Pharma, Inc. (SILO) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
SILO · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 13, 2026EPS Actual
-$1.80
Est. -$0.32 · -462.5%
Revenue
$0.00B
Est. $0.00B · +0.1%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 13, 2026
After Market Close
▼ Miss EPS
SILO reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$1.19
Rev. $0.35B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$1.19
Rev. Est.$0.35B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Sep 2, 2026 | -$0.32 | — | — | — | $0.00B | — |
| ▼ Q2 FY2026 | May 13, 2026 | -$0.32 | -$1.80 | -462.5% | $0.00B | $0.00B | +0.1% |
| — Q1 FY2026 | Mar 27, 2026 | — | -$0.99 | — | $0.00B | — | — |
| ▲ Q4 FY2025 | Nov 13, 2025 | -$0.20 | -$0.12 | +40.0% | $0.00B | $0.00B | +0.1% |
| ▲ Q3 FY2025 | Aug 13, 2025 | -$0.20 | -$0.19 | +5.0% | $0.00B | $0.00B | +0.1% |
| ▼ Q2 FY2025 | May 9, 2025 | -$0.21 | -$0.23 | -9.5% | $0.00B | $0.00B | +0.1% |
| ▼ Q1 FY2025 | Mar 28, 2025 | -$0.20 | -$0.41 | -105.0% | $0.00B | $0.00B | +0.1% |
| ▼ Q4 FY2024 | Nov 12, 2024 | -$0.21 | -$0.22 | -4.8% | $0.00B | $0.00B | +0.1% |
Q3 FY2026
Sep 2, 2026
EPS Actual
—
EPS Est.
-$0.32
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 13, 2026Miss
EPS Actual
-$1.80
EPS Est.
-$0.32
EPS Surpr.
-462.5%
Revenue
$0.00B
Q1 FY2026
Mar 27, 2026
EPS Actual
-$0.99
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q4 FY2025
Nov 13, 2025Beat
EPS Actual
-$0.12
EPS Est.
-$0.20
EPS Surpr.
+40.0%
Revenue
$0.00B
Q3 FY2025
Aug 13, 2025Beat
EPS Actual
-$0.19
EPS Est.
-$0.20
EPS Surpr.
+5.0%
Revenue
$0.00B
Q2 FY2025
May 9, 2025Miss
EPS Actual
-$0.23
EPS Est.
-$0.21
EPS Surpr.
-9.5%
Revenue
$0.00B
Q1 FY2025
Mar 28, 2025Miss
EPS Actual
-$0.41
EPS Est.
-$0.20
EPS Surpr.
-105.0%
Revenue
$0.00B
Q4 FY2024
Nov 12, 2024Miss
EPS Actual
-$0.22
EPS Est.
-$0.21
EPS Surpr.
-4.8%
Revenue
$0.00B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q1 FY2027 | $-3.00 | $-3.00 | $-3.00 | 1 |
| Q4 FY2026 | $-3.15 | $-3.15 | $-3.15 | 1 |
| Q3 FY2026 | $-4.80 | $-4.80 | $-4.80 | 1 |
| Q2 FY2026 | $-0.32 | $-0.32 | $-0.32 | 1 |
| Q1 FY2026 | $-0.32 | $-0.32 | $-0.32 | 1 |
| Q3 FY2025 | $-0.20 | $-0.20 | $-0.20 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 13, 2026 | -462.5% | $5.94 | $5.85 | -1.52% |
| — Q1 FY2026 | Mar 27, 2026 | — | $5.69 | $5.10 | -10.37% |
| ▲ Q4 FY2025 | Nov 13, 2025 | +40.0% | $6.77 | $6.53 | -3.55% |
| ▲ Q3 FY2025 | Aug 13, 2025 | +5.0% | $10.11 | $10.51 | +3.96% |
| ▼ Q2 FY2025 | May 9, 2025 | -9.5% | $12.22 | $12.22 | +0.00% |
| ▼ Q1 FY2025 | Mar 28, 2025 | -105.0% | $19.80 | $18.75 | -5.30% |
| ▼ Q4 FY2024 | Nov 12, 2024 | -4.8% | $19.80 | $18.45 | -6.82% |
| ▲ Q3 FY2024 | Aug 13, 2024 | +3.1% | $19.50 | $18.75 | -3.85% |
Q2 FY2026-1.52%
Report Date
May 13, 2026
EPS Beat/Miss
-462.5%
Price Before
$5.94
Price After
$5.85
Q1 FY2026-10.37%
Report Date
Mar 27, 2026
EPS Beat/Miss
—
Price Before
$5.69
Price After
$5.10
Q4 FY2025-3.55%
Report Date
Nov 13, 2025
EPS Beat/Miss
+40.0%
Price Before
$6.77
Price After
$6.53
Q3 FY2025+3.96%
Report Date
Aug 13, 2025
EPS Beat/Miss
+5.0%
Price Before
$10.11
Price After
$10.51
Q2 FY2025+0.00%
Report Date
May 9, 2025
EPS Beat/Miss
-9.5%
Price Before
$12.22
Price After
$12.22
Q1 FY2025-5.30%
Report Date
Mar 28, 2025
EPS Beat/Miss
-105.0%
Price Before
$19.80
Price After
$18.75
Q4 FY2024-6.82%
Report Date
Nov 12, 2024
EPS Beat/Miss
-4.8%
Price Before
$19.80
Price After
$18.45
Q3 FY2024-3.85%
Report Date
Aug 13, 2024
EPS Beat/Miss
+3.1%
Price Before
$19.50
Price After
$18.75
Avg Beat Reaction-1.15%
Avg Miss Reaction-3.41%
Beat Rate3 / 8 quarters
Largest Move-10.37% (Q1 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: SILO ends December
Silo Pharma, Inc. (SILO) most recently reported earnings on May 13, 2026 for Q2 FY2026, posting EPS of $-1.80 — missing the analyst consensus of $-0.32 by -462.5%. The next SILO earnings date is expected around September 1, 2026.
Each quarter, investors track SILO earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. SILO revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
SILO's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
SILO earnings · 5 questionsSilo Pharma, Inc.'s next earnings report is expected around September 1, 2026. SILO typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; SILO historically reports after market close (AMC).
SILO earnings datewhen is SILO earningsSILO next earnings datewhen does SILO report earningsSILO earnings calendar
▸ Source: FMP · Silo Pharma, Inc. SEC filings · US GAAP · Silo Pharma, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026